d) inoculating cells from said monolayer into a plurality of segregated sites;

e) treating said plurality of sites with at least one treating means, determining cell number relative to at least one control, followed by correlating the chemosensitivity of the cells in said plurality of sites to said at least one treating means in order to assess the chemosensitivity of the patient cells; and

f) assessing said plurality of sites, at least one of which further constitutes a control site, for cellular markers, secreted factors, or tumor antigens.

24. The method according to claim 23 wherein step e) further comprises:

e) treating said plurality of sites with a plurality of active agents over a length of time adequate to permit assessment of both initial cytotoxic effect and longer-term inhibitory effect of at least one of said plurality of active agents.

25. The method according to claim 23 wherein said secreted factors are selected from the group consisting of plasminogen activator inhibitors type 1 (PAI-1), eurokinase-type plasminogen activator (u-PA), α-fetoprotein, carcinoembryonic antigen, transforming growth factor α, transforming growth factor β and major histocompatibility complex (MHC molecules).

26. The process according to claim 23 wherein said treating means is a wound healing agent.

27. The method according to claim 23 wherein said treating means is a radiation therapy and/or a radiation therapy sensitizing or ameliorating agent.

28. The method according to claim 23 wherein said treating means is an immunotherapeutic agent.

29. The method according to claim 23 comprising the further step of

g) sampling a quantity of medium from the tissue culture monolayer of step c) to identify the presence or absence of cellular markers, secreted factors or tumor antigens indicative of a disease state.

30. The method according to claim 23 wherein said treating is a gene therapy agent.

C 1 concl'd

31. The method according to claim 23 wherein said treating means is an antisense oligonucleotide gene therapy agent.

32. The method according to claim 23 where said treating means further comprises a combination of two or more therapeutic agents.

REMARKS

This Continued Prosecution Application is being submitted in response to the final Office Action dated March 30, 2000 in the above-identified patent application, and further to zero in on claims which embrace the newly-added subject matter in this Continued Prosecution Application.